GlassScriptPhysician profile
Sikander Kajani
NPI 1851380992
$6,670.05
in general payments reported to CMS, 2019-2025
33 companies · $567 in 2025
The $567 reported for 2025 was more than what 81% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,878 · 2020: $1,581 · 2021: $1,019 · 2022: $311 · 2023: $488 · 2024: $826 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,880.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,786.70 | 2019-2024 | Spravato, Xarelto |
| Amgen INC. | $861.18 | 2019-2024 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $684.12 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $341.40 | 2019-2025 | Mounjaro, Kisunla, Jardiance |
| Pfizer INC. | $341.29 | 2019-2024 | |
| Glaxosmithkline, LLC. | $337.04 | 2019-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $322.29 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.45 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amarin Pharma, INC. | $216.30 | 2019-2021 | |
| Novo Nordisk INC | $160.28 | 2021-2024 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $151.24 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.60 | 2022-2024 | |
| Astellas Pharma US INC | $135.95 | 2019-2020 | |
| Neurelis, INC. | $123.92 | 2024-2025 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $117.57 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $81.71 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $81.39 | 2025 | Daybue |
| Sanofi-Aventis U.S. LLC | $66.44 | 2025 | |
| Phathom Pharmaceuticals, INC. | $61.28 | 2024-2025 | Voquezna |
| Abbvie INC. | $56.32 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $52.14 | 2022-2023 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $47.07 | 2024 | Rexulti |
| Vifor Pharma, INC. | $33.66 | 2024 | Veltassa |
| Zyla Life Sciences, INC. | $29.13 | 2019 | |
| Philips North America LLC | $26.54 | 2024 | (8874) Incourage |
| Fidia Pharma USA INC. | $22.16 | 2024 | Hyalgan, Hymovis, Triluron |
| Avanir Pharmaceuticals, INC. | $20.75 | 2019 | |
| Allergan, INC. | $20.14 | 2020 | |
| Exact Sciences Corporation | $19.63 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $18.82 | 2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.67 | 2025 | Xifaxan |
| Eisai INC. | $18.66 | 2021 | |
| Electromed, INC. | $16.21 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sikander Kajani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.